Hydroxamic acid - A novel molecule for anticancer therapy

Journal of Advanced Pharmaceutical Technology and Research

Volumn 3, Issue 2, 2012, Pages 92-99

  Pal, Dilipkumar ^a   Saha, Supriyo ^b  

^a GURU GHASIDAS UNIVERSITY   (India)

^b Himalayan Institute of Pharmacy and Research   (India)

Author keywords

Cancer; Histone deacetylase; Hydroxamic acid; MMP inhibitor

Indexed keywords

3 (4 AROYL 1 METHYL 1H PYRROL 2 YL) N HYDROXY 2 PROPENAMIDE; 4 (3 PYRIDYL)PHENYLHYDROXAMIC ACID; 5 PYRIDIN 2 YL THIOPHENE 2 HYDROXAMIC ACID; 7 [4 (DIMETHYLAMINO)PHENYL] N HYDROXY 4,6 DIMETHYL 7 OXOHEPTA 2,4 DIENAMIDE; AMINO SUBEROYLHYDROXAMIC ACID; ARYL ETHER HYDROXAMIC ACID; BENZOFURANONE HYDROXAMIC ACID; BIPHENYL 4 YL ACRYLOHYDROXAMIC ACID; BUTYLATED HYDROXYANISOLE; CISPLATIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; N (2 AMINOPHENYL) 4 [(4 PYRIDIN 3 YLPYRIMIDIN 2 YLAMINO)METHYL]BENZAMIDE; N (6 OXO 7 PHENYLHEPTYL) 2 SULFANYLETHANETHIOAMIDE; N 2 DIHYDROXYBENZAMIDE; N HYDROXY 2 [4 (NAPHTHALENE 2 YLSULFONYL)PIPERAZIN 1 YL]PYRIMIDINE 5 CARBOXAMIDE; N HYDROXY 3 PHENOXYBENZAMIDE; N HYDROXY 4 (4 PHENYLBUTYRYLAMINO)BENZAMIDE; N HYDROXY 8 OXO 9 PHENYLNONAMETHIOAMIDE; N HYDROXYBIPHENYL 3 CARBOXAMIDE; N HYDROXYHEPTAN 3 AMIDE; N HYDROXYNAPHTHALENE 1 CARBOXAMIDE; SALICYHYDROXAMIC ACID; THIAZOLE 5 HYDROXAMIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 84866433051     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.97281     Document Type: Article

References (30)

1. Mai A, Massa S, Lavu S, Pezzi R, Simeoni S, Ragno R. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem 2005;48:7789-95 (Pubitemid 41698818)
2. Ragno R, Mai A, Massa S, Cerbara I, Valente S, Bottoni P, et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies. J Med Chem 2004;47:1351-9
3. Kim DK, Lee JY, Kim JS, Ryu JH, Choi JY, Lee JW, et al. Synthesis and Biological Evaluation of 3-(4-Substituted-phenyl)-N-hydroxy- 2-propenamides, a New Class of HistoneDeacetylase Inhibitors. J Med Chem 2003;46:5745-51 (Pubitemid 37543324)
4. Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005;48:5530-5 (Pubitemid 41209250)
5. Belvedere S, Witter DJ, Yan J, Secrist JP, Richon V, Miller TA. Aminosuberoylhydroxamic acids (ASHAs): A potent new class of HDAC inhibitors Bioorg. Med Chem Lett 2007;17:3969-71 (Pubitemid 46920932)
6. Lee S, Shinji C, Ogura K, Shimizu M, Maeda S, Sato M, et al. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007;17:4895-900 (Pubitemid 47193186)
7. Price S, Bordogna W, Braganza R, Bull RJ, Dyke HJ, Gardan S, et al. Identification and optimisation of a series of substituted 5-pyridin- 2-yl-thiophene-2-hydroxamic acids as potenthistone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007;17:363-9 (Pubitemid 46073760)
8. Hanessian S, Auzzas L, Giannini G, Marzi M, Cabri W, Barbarino M, et al. w-Alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: A study of chain-length and stereochemical dependence Bioorg Med ChemLett 2007;17:6261-5 (Pubitemid 47559125)
9. Anandan SK, Ward JS, Brokx RD, Denny T, Bray MR, Patel DV, et al. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors Bioorg Med ChemLett 2007;17: 5995-9 (Pubitemid 47449745)
10. Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, et al. Design, synthesis, and evaluation of biphenyl-4-ylacrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur. J Med Chem 2009;44:1900-12
11. Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, et al. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J Med Chem 2009;52:2909-22
12. Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, et al. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J Med Chem 2009;52:3112-5
13. Koncic MZ, Rajic Z, Petric N, Zorc B. Antioxidant activity of NSAID hydroxamic acids. Acta Pharm 2000;59:235-42
14. Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005;48:5530-5 (Pubitemid 41209250)
15. Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, et al. Discovery of N-(2-Aminophenyl)- 4- [(4-pyridin-3-ylpyrimidin-2- ylamino)methyl]benzamide (MGCD0103),an Orally Active Histone Deacetylase Inhibitor. J Med Chem 2008;51:4072-5 (Pubitemid 352032434)
16. Pabba C, Gregg BT, Kitchen DB, Chen ZJ, Judkins A. Design and synthesis of aryl ether and sulfonehydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2011;21:324-8
17. Angibaud P, Arts J, Emelen KV, Poncelet V, Pilatte I, Roux B, et al. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. Eur J Med Chem 2005;40:597-606 (Pubitemid 40740208)
18. Codd R, Braich N, Liu J, Soe CZ, Pakchung AA. Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilidehydroxamic acid and trichostatin A. Int J Biochem Cell Biol 2009;41:736-9
19. Gu W, Nusinzon I, Smith RD, Horvath CM, Silverman RB. Carbonyland sulfur-containing analogs of suberoylanilidehydroxamic acid: Potent inhibition of histone deacetylases. Bioorg Med Chem 2006;14:3320-9
20. Rajak H, Agarawal A, Parmar P, Thakur BS, Veerasamy R, Sharma PC, et al. 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Bioorg Med Chem Lett 2011;21:5735-8
21. Jiao J, Fang H, Wang X, Guan P,Yuan Y, Xu W. Design, synthesis and preliminary biological evaluation of N-hydroxy- 4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histonedeacetylase inhibitors. Eur J Med Chem 2009;30:1-7
22. Mshvidobadze EV, Vasilevskya SF, Elguero J. A new route to pyrazolo[3,4-c] and [4,3-c]pyridinones via heterocyclization of vicsubstituted hydroxamic acids of acetylenylpyrazoles. Tetrahedron 2004;60:11875-8 (Pubitemid 39487437)
23. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, et al. Enhancement of cisplatin induced apoptosis by suberoylanilidehydroxamic acid in human oral squamous cell carcinoma cell lines. Bio Pharmaco 2007;73:1901-9 (Pubitemid 46677907)
24. Hrubec KK, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;2874-8 (Pubitemid 46636249)
25. Wang CY, Lee LH. A. Mutagenicity and antibacterial activity of hydroxamic acids. AmSocMicrobiol 1977;11:753-5 (Pubitemid 8093341)
26. Davis A, Hulme KL, Wilson GT, Mccord TJ. In vitro antimicrobial activity of some cyclic hydroxamic acids and related lactams. AmSocMicrobiol 1978;13:542-4 (Pubitemid 8334746)
27. Brien EC, Farkas E, Gil MJ, Fitzgerald D, Castineras A, Nolan KB. Metal complexes of salicylhydroxamic acid (H2Sha), anthranilichydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)2(Cl)] ClPH2Sha, a model for a peroxidase inhibitor complex. J Inorg Biochem 2000;79:47-51
28. Kokare ND, Nagawade RR, Ranea VP, Shinde DB. Design, synthesis and utilization of a novel coupling reagent for the preparation of O-alkyl hydroxamic acids. Tetrahedron Lett 2007;48:4437-40 (Pubitemid 46776779)
29. Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg Med Chem Lett 2004;14:3389-95 (Pubitemid 38744529)
30. Tommasi RA, Weiler S, McQuire LW, Rogel O, Chambers M, Clark K, et al. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13. Bioorg Med Chem Lett 2011;21:6440-5.